Literature DB >> 18950958

Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma.

Freda H Passam1, Michael G Alexandrakis, Maria Kafousi, Marianthi Fotinou, Katerina Darivianaki, George Tsirakis, Paraskevi A Roussou, Efstathios N Stathopoulos, Nikolaos M Siafakas.   

Abstract

Angiogenesis is a prerequisite for solid tumor growth, but there is relatively limited data regarding Hodgkin lymphoma. The purpose of this study was to examine the immunohistochemical expression of angiogenic and proliferation markers in Hodgkin biopsies in relation to clinical parameters. Immunostaining was performed on 65 Hodgkin biopsies with vascular endothelial growth factor (VEGF), hypoxia inducible factor-1 alpha (HIF-1alpha), platelet-derived growth factor receptor alpha (PDGFRalpha), Ki-67, and p53. Microvessel density (MVD) was determined by CD31 staining. In all cases, neoplastic cells and reactive background cells were evaluated. The neoplastic population expressed VEGF in 48% of the cases, HIF-1alpha in 54% of the cases, and PDGFRalpha in 95% of the cases. Both Ki-67 and p53 were positive in neoplastic cells in over 60% of the cases. The MVD had a median of 2.6/0.0625mm(2) which was not different from normal lymph nodes. VEGF in the non-neoplastic compartment showed increased staining in Ann Arbor stage I-II versus III-IV. In conclusion, VEGF, HIF-1alpha, and predominantly PDGFRalpha are expressed in neoplastic cells in the majority of Hodgkin lymphomas. As microvessel formation is not increased in Hodgkin, additional functions of these angiogenic molecules should be investigated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18950958     DOI: 10.1016/j.prp.2008.07.007

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  11 in total

1.  Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma.

Authors:  C A Pappa; G Tsirakis; M Devetzoglou; M Zafeiri; R Vyzoukaki; A Androvitsanea; A Xekalou; K Sfiridaki; M G Alexandrakis
Journal:  Tumour Biol       Date:  2014-02-23

Review 2.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

3.  Stimulation of the hypoxia pathway modulates chemotherapy resistance in Hodgkin's lymphoma cells.

Authors:  Stefanie Kewitz; Lars Kurch; Ines Volkmer; Martin S Staege
Journal:  Tumour Biol       Date:  2015-12-30

4.  Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET.

Authors:  K A Miles; R E Williams; D Yu; M R Griffiths
Journal:  Int J Mol Imaging       Date:  2011-04-26

5.  CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma.

Authors:  Young Wha Koh; Chan-Sik Park; Dok Hyun Yoon; Cheolwon Suh; Jooryung Huh
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

Review 6.  Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy.

Authors:  Marius Raica; Anca Maria Cimpean
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-11

7.  Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience.

Authors:  Talita Máira Bueno da Silveira da Rocha; Sergio Costa Fortier; Thais Rodrigues da Cunha Fischer; Guilherme Fleury Perini; Rafael Dezen Gaiolla; Laura Fogliatto; Marcia Torresan Delamain; Andressa Fragoso da Costa; Nelson Siqueira de Castro; Wolney Gois Barretos; Cármino Antonio de Souza; Valéria Buccheri; Carlos Sérgio Chiattone
Journal:  Rev Bras Hematol Hemoter       Date:  2017-05-11

Review 8.  The hypoxia signalling pathway in haematological malignancies.

Authors:  Marta Irigoyen; Juan Carlos García-Ruiz; Edurne Berra
Journal:  Oncotarget       Date:  2017-05-30

9.  Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1α/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells.

Authors:  Fei Wang; Wei Zhang; Liting Guo; Wen Bao; Nan Jin; Ran Liu; Ping Liu; Yonghui Wang; Qinglong Guo; Baoan Chen
Journal:  Cancer Sci       Date:  2014-07-27       Impact factor: 6.716

10.  EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.

Authors:  Chunrong Li; James C Romero-Masters; Shane Huebner; Makoto Ohashi; Mitchell Hayes; Jillian A Bristol; Scott E Nelson; Mark R Eichelberg; Nicholas Van Sciver; Erik A Ranheim; Rona S Scott; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2020-06-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.